SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10 - Q/A
AMENDMENT NO. 1
[X] AMENDMENT TO QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1995
OR
[ ] AMENDMENT TO TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to ______________
COMMISSION FILE NUMBER 1-10352
COLUMBIA LABORATORIES, INC.
(Exact name of Company as specified in its charter)
DELAWARE 59-2758596
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2665 SOUTH BAYSHORE DRIVE
MIAMI, FLORIDA 33133
(Address of principal executive offices) (Zip Code)
Company's telephone number, including area code: (305) 860-1670
Indicate by check mark whether the Company (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the Company was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes X No __
Number of shares of the Common Stock of Columbia Laboratories, Inc.
issued and outstanding as of April 30, 1995: 25,122,265
<PAGE>
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its Quarterly Report for the quarter
ended March 31, 1995 on Form 10-Q as set forth in the pages attached hereto:
Supplemental Schedule of Noncash Operating and Financing
Activities on page 6 of 12 to disclose the total amount of
debt repaid through the issuance of Common Stock during 1995.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf by the
undersigned, thereunto duly authorized.
COLUMBIA LABORATORIES, INC.
Date July 17, 1995 By Margaret J. Roell
------------- -----------------
Margaret J. Roell
Vice President-Finance
and Administration, Chief
Financial Officer
Secretary and Treasurer
<PAGE>
<TABLE>
<CAPTION>
COLUMBIA LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Continued)
Three Months Ended March 31,
1995 1994
---------- ----------
<S> <C> <C>
EFFECT OF EXCHANGE RATE CHANGES ON CASH (80,614) 103,975
---------- ----------
NET DECREASE IN CASH
AND CASH EQUIVALENTS (263,955) (3,525,582)
CASH AND CASH EQUIVALENTS,
beginning of period 689,749 5,280,829
----------- ----------
CASH AND CASH EQUIVALENTS,
end of period $ 425,794 $1,755,247
=========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid during the period $ 12,435 $ -
=========== ==========
</TABLE>
SUPPLEMENTAL SCHEDULE OF NONCASH OPERATING AND FINANCING ACTIVITIES:
During the three months ended March 31, 1995, the Company issued 85,382
shares of Common Stock in payment of accrued interest, which totaled $310,362.
In addition, the Company issued 1,188,523 shares of Common Stock in repayment of
long-term debt which totaled $4,476,707.
During the three months ended March 31, 1994, the Company issued 2,808
shares of Common Stock in payment of consulting fees, which totaled $15,000.
As of March 31, 1995, dividends on the Series A Preferred Stock of
$89,731 ($2,988 relating to the three months ended March 31, 1995) have been
earned but have not been declared and are included in other long-term
liabilities in the March 31, 1995 condensed consolidated balance sheet.
See notes to condensed consolidated financial statements
